Table 2.
Updated list of ongoing clinical trials in 2012
| Trial | Phase | Diseasea | Schedulingb | Radiotherapy regimec | Chemotherapy | Statusd | Remark/publication |
|---|---|---|---|---|---|---|---|
| Bevacizumab | |||||||
| NCT00570531 | II | EC (locoregional) | Conc | 25 × xGy | Paclitaxel/cisplatin/5-FU | 4 | Insufficient number of participants |
| NCT00354679 | II | ES (LA) | Neo/conc | 30 × xGy | Cisplatin/irinotecan | 1 | Results, unpublished |
| NCT01332929 | I | Brain metastases | Neo/conc | 15 × 2 or 10 × 3 Gy | 1 | Levy et al. [109] | |
| NCT00817284 | II | GBM | Neo/conc | 30 × 2 Gy | Temozolomide vs irinotecan | 1 | No results/publications |
| NCT00805961 | II | GBM (first-line treatment) | Conc/adj | 30 × 2 Gy | Temozolomide/everolimus | 1 | Hainsworth et al. [77] |
| NCT00590681 | II | GBM (ND) | Adj | 30–33 × 1.8–2.0 Gy | Temozolomide | 1 | No results/publications |
| NCT01186406 | II | GBM (ND) | Conc/adj | 30 × 2 Gy | Gliadel/temozolomide | 2 | Results, no publications |
| NCT00884741 | III | GBM (ND) | Conc/adj | 30 × xGy | Temozolomide | 1 | Gilbert et al. [65] |
| NCT00943826 | III | GBM (ND) | Neo/conc | 30 × 2 Gy | Temozolomide | 1 | Chinot et al. [64] |
| NCT01102595 | II | GBM (unresectable) | Neo/conc | 30 × 2 Gy | Temozolomide | 1 | No results/publications |
| NCT01022918 | II | GBM (unresectable) | Neo/adj | 30 × 2 Gy | Temozolomide/irinotecan | 1 | Chauffert et al. [72] |
| NCT00597402 | II | GBM and gliosarcomas | Conc/adj | 33 × xGy | Temozolomide/irinotecan | 1 | Results, no publications |
| NCT01209442 | II | GBM | Conc/adj | 60 Gy in 2 weeks | Temozolomide | 2 | No results/publications |
| NCT01013285 | II | GBM or gliosarcoma (ND) | Conc/adj | 30 × xGy | Temozolomide | 2 | No results/publications |
| NCT01443676 | II | GBM (eldery patient) | Conc | Unknown | 1 | No results/publications | |
| NCT00369122 | II | Cervical cancer (LA) | Conc | 45 Gy in 25 fractions | Cisplatin | 1 | Results, unpublished |
| NCT00545792 | II | Gynecological cancer (recurrent) | Conc | 45 Gy in 25 fractions | 1 | Viswanathan et al. [78] | |
| NCT00703976 | II | HNSCC (LA) | Conc | 35 × 2 Gy | Cetuximab/pemetrexed | 1 | No results/publications |
| NCT00281840 | II | HNSCC (stage III/IV) | Conc/adj | 40 × 1.8 Gy | Docetaxel | 1 | Yao et al. [76] |
| NCT01004874 | II | Malignant glioma (grade IV) | Conc/adj | Standard Rth for 6.5 weeks | Temozolomide/topotecan | 2 | Results, no publications |
| NCT00782756 | II | Malignant glioma (ND) | Neo/conc/adj | 3 × xGy/week for 2 weeks | Temozolomide | 2 | No results/publications |
| NCT01478321 | II | High-grade recurrent malignant glioma | Conc/adj | 25 × xGy | Temozolomide | 3 | No results/publications |
| NCT00387374 | II | NCSLC (stage IIIB/IV unresectable) | Adj | 10 × xGy | Carboplatin/paclitaxel | 1 | No results/publications |
| NCT00896181 | II | NPC (advanced) | Neo/conc | 30–35 × xGy | Doxatel/cisplatin/5-FU/carboplatin | 3 | No results/publications |
| NCT00408694 | II | NPC (stage IIB–VB) | Conc/adj | 33 × 2.12 Gy | Cisplatin/5-FU | 1 | Lee et al. [74] |
| NCT00334815 | I/II | NSCLC (stage III irresectable) | Conc | 35 × xGy | Cisplatin/etoposide | 2 | Results, unpublished |
| NCT00402883 | II | NSCLC (stage III) | Conc/adj | 35 × 1.8 Gy | Pemetrexed/carboplatin | 4 | Toxicity |
| NCT00578149 | II | NSCLC (stage III) | Conc/adj | 35 × xGy | Paclitaxel/carboplatin | 1 | No results/publications |
| NCT00307723 | I/II | Pancreatic cancer | Conc | 35 × xGy | Oxaliplatin/5-FU | 4 | Insufficient number of patients |
| NCT00336648 | II | Pancreatic cancer | Conc/adj | 28 × 1.8 Gy | Gemcitabine | 1 | No results/publications |
| NCT00460174 | II | Pancreatic cancer (localized) | Neo | 15 × 2.4 Gy | Gemcitabine | 1 | Rezai et al. [110] |
| NCT00557492 | II | Pancreatic cancer (potentially resectable) | Conc/adj | 10 × 3 Gy | Gemcitabine | 2 | Results, unpublished |
| NCT00349557 | II | Prostate cancer (high risk) | Conc/adj | IMRT | Bicalutamide | 1 | No results/publications |
| NCT00321685 | II | RC (LA non-metastatic) | Conc | 28 × 1.8 Gy | Capecitabine/oxaliplatin (FOLFOX) | 1 | Landry et al. [73] |
| NCT00113230 | II | RC (LA) | Conc | 28 × 1.8 Gy | Capecitabine | 1 | Results, unpublished |
| NCT01434147 | II | RC (LA) | Neo | 25 × 1.8 Gy | Capecitabine/oxaliplatin | 1 | No results/publications |
| NCT00557713 | II | RC (LA) | Neo/conc | 28 × 1.8 Gy | Oxaliplatin/capecitabine | 5 | No results/publications |
| NCT00842686 | II | RC (LA) | Neo/conc | 28 × 1.8 Gy | Capecitabine | 5 | No results/publications |
| NCT00865189 | II | RC (LA) | Neo/conc | 25 × 1.8 Gy | FOLFOX/5-FU | 1 | Borg et al. [71] |
| NCT01043484 | II | RC (localized) | Conc | 25 × 1.8 Gy | Capecitabine | 1 | Salazar et al. [75] |
| NCT00308516 | II | RC (stage II/III) | Conc/adj | 28 × 1.8 Gy | FU/FOLFOX6 | 1 | Spigel et al. [83] |
| NCT01481545 | II | RC (poor risk) | Conc/adj | 25 × 1.8 Gy | 2 | No results/publications | |
| NCT00356031 | II | Sarcoma | Neo | 30 × xGy | 5 | No results/publications | |
| NCT00308529 | II | SCLC (LA) | Neo/conc/adj | 34 × 1.8 Gy | Irinotecan/carboplatin | 1 | Spigel et al. [111] |
| NCT00387699 | II | SCLC (limited stage) | Conc/adj | 15 × twice daily xGy | Cisplatin/etoposide | 1 | No results/publications |
| Bevacizumab/erlotinib | |||||||
| NCT00393068 | II | EC (operable) | Conc | 25 × 1.8 Gy | 5-FU/paclitaxel/carboplatin | 1 | Bendell et al. [70] |
| NCT00720356 | II | GBM or gliosarcoma (ND) | Conc/adj | 30 × xGy | Temozolomide | 2 | No results/publications |
| NCT00140556 | I | HNSCC/NPC | Conc | 70 Gy in twice daily 1.25 Gy | Cisplatin | 1 | Yoo et al. [87] |
| NCT00392704 | II | HNSCC (LA) | Neo/conc | 38 × 1.8 Gy | Paclitaxel/carboplatin/5-FU | 1 | Hainsworth et al. [112] |
| NCT00280150 | I/II | NSCLC (stage III) | Conc | 74 Gy in 35 fractions | Carboplatin | 1 | No results/publications |
| NCT00614653 | I | Pancreatic cancer | Conc | 28 × 1.8 Gy | Capecitabine | 1 | No results/publications |
| NCT00735306 | I/II | Pancreatic cancer | Conc | 28 × 1.8 Gy | Raltitrexed/oxaliplatin/5-FU | 1 | Results, unpublished |
| NCT00307736 | I/II | RC (LA) | Conc | 28 × 1.8 Gy | 5-FU | 1 | Blaszkowsky et al. [113] |
| NCT00543842 | I/II | RC (LA) | Conc | 28 × 1.8 Gy | Capecitabine | 1 | No results/publications |
| Bevacizumab/cetuximab | |||||||
| NCT00703976 | II | HNSCC (LA) | Conc/adj | 35 × 2 Gy | Pemetrexed | 1 | No results/publications |
| NCT01262859 | II | HNSCC (LA) | Neo/con | 35–37 × 2 Gy | Cisplatin | 4 | No results/publications |
| NCT00968435 | II | HNSCC (stage III/IV) | Neo/conc | 70 Gy in 33 fractions | Cisplatin | 1 | No results/publications |
| Endostar/endostatin | |||||||
| NCT01158144 | II | NSCLC (LA) | Conc | 30–33 × 2 Gy | Paclitaxel/carboplatin | 1 | Sun et al. [104] |
| NCT01218594 | II | NSCLC (LA) | Neo/conc/adj | 30–33 × 2 Gy | Doxatel/cisplatin | 1 | Bao et al. [102] |
| NCT01211002 | IV | NSCLC (LA) | Conc | 30–33 × 2 Gy | Etoposide/cisplatin | 5 | No results/publications |
| Sorafenib | |||||||
| NCT00822848 | I | Soft tissue sarcoma | Neo/conc | 28 Gy in eight fractions | Epirubicin/Ifosfamide | 2 | No results/publications |
| NCT00610246 | I | Cancer (not eligible for curative treatment) | Neo/conc/adj | X × xGy | 1 | No results/publications | |
| NCT00544817 | II | GBM (postsurgical) | Adj | 30 × 2.0 Gy | Temozolomide | 1 | Hainsworth et al. [92] |
| NCT00892658 | I | HCC | Neo/conc/adj | Three fractions in 2 weeks | 2 | No results/publications | |
| NCT01328223 | II | HCC (advanced) | Conc/adj | 23–24 × 2.0–2.5 Gy | 5 | No results/publications | |
| NCT00892424 | I/II | Liver metastasis (unresectable) | Neo/conc | 3 × xGy/week for 2 weeks | 2 | No results/publications | |
| NCT00609934 | I/II | RCC with bone metastasis | Conc/adj | 10 × 3 Gy | 1 | No results/publications | |
| SU5416 | |||||||
| NCT00023725 | I/II | Soft tissue sarcoma | Neo/conc/adj | 25 × xGy | 1 | No results/publications | |
| NCT00023738 | I/II | Soft tissue sarcoma | Conc/adj | 2 cycles of 11 × xGy | Doxorubicin/ifosfamide/dacarbazine | 1 | No results/publications |
| NCT01308034 | I | Non-GIST Sarcomas | Conc | 30 × xGy | 2 | No results/publications | |
| Sunitinib | |||||||
| NCT01100177 | II | GBM (ND) | Neo/conc | 30 × 2 Gy | 1 | No results/publications | |
| NCT01498835 | I | Soft tissue sarcoma | Conc | 28 x 1.8 Gy | 1 | Jakob et al. [96, 114] | |
| NCT00753727 | I/II | Soft tissue sarcoma | Neo/conc | 28 × 1.8 Gy | 5 | No results/publications | |
| NCT00631527 | I | Prostate cancer | Conc | 40 fractions of xGy | Hormone therapy | 1 | No results/publications |
| Thalidomide | |||||||
| NCT00049361 | II | Brain metastases (ND) | Conc/adj | 15 × xGy | Temozolomide | 1 | No results/publications |
| NCT00033254 | III | Brain metastases | Conc/adj | 15 × 2.5 Gy | 1 | No results/publications | |
| Vandetanib | |||||||
| NCT00745732 | I/II | NSCLC | Neo/conc | 15 × 3 or 33–35 × 2 Gy | 4 | Sponsor withdrew support | |
aDisease: RCC renal cell carcinoma, LA locally advanced, HNSCC head and neck squamous cell cancer, NSCLC non-small cell lung cancer, EC esophageal cancer, RC rectal cancer, ND newly diagnosed, GBM glioblastoma, NPC nasopharyngeal cancer, HCC hepatocellular carcinoma, SCLC small cell lung cancer
bScheduling: scheduling of angiostatic drug to radiotherapy neo neoadjuvant, conc concurrent, adj adjuvant
cRadiotherapy: Rth is applied at a frequency of 5 days/week unless indicated otherwise. When the dose applied is unknown, this is indicated with × Gy
dStatus: 1 = completed; 2 = active, not recruiting; 3 = recruiting; 4 = terminated/withdrawn; 5 = unknown